Woźniak, E.; Woźniak, A.; Pawlos, A.; Broncel, M.; Satała, J.; Bukowska, B.; Gorzelak-Pabiś, P.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. Int. J. Mol. Sci. 2025, 26, 10529.
https://doi.org/10.3390/ijms262110529
AMA Style
Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, Gorzelak-Pabiś P.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. International Journal of Molecular Sciences. 2025; 26(21):10529.
https://doi.org/10.3390/ijms262110529
Chicago/Turabian Style
Woźniak, Ewelina, Agnieszka Woźniak, Agnieszka Pawlos, Marlena Broncel, Joanna Satała, Bożena Bukowska, and Paulina Gorzelak-Pabiś.
2025. "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia" International Journal of Molecular Sciences 26, no. 21: 10529.
https://doi.org/10.3390/ijms262110529
APA Style
Woźniak, E., Woźniak, A., Pawlos, A., Broncel, M., Satała, J., Bukowska, B., & Gorzelak-Pabiś, P.
(2025). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. International Journal of Molecular Sciences, 26(21), 10529.
https://doi.org/10.3390/ijms262110529